JPWO2021176017A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021176017A5 JPWO2021176017A5 JP2022552577A JP2022552577A JPWO2021176017A5 JP WO2021176017 A5 JPWO2021176017 A5 JP WO2021176017A5 JP 2022552577 A JP2022552577 A JP 2022552577A JP 2022552577 A JP2022552577 A JP 2022552577A JP WO2021176017 A5 JPWO2021176017 A5 JP WO2021176017A5
- Authority
- JP
- Japan
- Prior art keywords
- caused
- pharmaceutical composition
- disease
- coronavirus
- cbm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 12
- 241000711573 Coronaviridae Species 0.000 claims 10
- 208000024891 symptom Diseases 0.000 claims 10
- 208000025721 COVID-19 Diseases 0.000 claims 9
- 241001678559 COVID-19 virus Species 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- 150000004676 glycans Chemical class 0.000 claims 6
- 241000607626 Vibrio cholerae Species 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 102000005348 Neuraminidase Human genes 0.000 claims 4
- 108010006232 Neuraminidase Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 229940096437 Protein S Drugs 0.000 claims 3
- 101710198474 Spike protein Proteins 0.000 claims 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 3
- 238000005829 trimerization reaction Methods 0.000 claims 3
- 229940118696 vibrio cholerae Drugs 0.000 claims 3
- 241000193468 Clostridium perfringens Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 101100239935 Streptococcus pneumoniae nanA gene Proteins 0.000 claims 2
- 108010038196 saccharide-binding proteins Proteins 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Claims (21)
（ｉ）ファミリー４０ ＣＢＭ；および
（ｉｉ）ファミリー３２ ＣＢＭ、
からなる群から選択される、請求項５に記載の医薬組成物。 CBM is:
(i) Family 40 CBM; and
(ii) Family 32 CBM ;
The pharmaceutical composition according to claim 5, selected from the group consisting of.
（ｉ）ウエルシュ菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｐｅｒｆｒｉｎｇｅｎｓ）ＣＢＭ３２（ＣｐＣＢＭ３２）；
（ｉｉ）肺炎レンサ球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）ＣＢＭ４０（ＳｐＣＢＭ４０）；
（ｉｉｉ）コレラ菌（Ｖｉｂｒｉｏ ｃｈｏｌｅｒａｅ）ＣＢＭ４０（ＶｃＣＢＭ４０）；
（ｉｖ）コレラ菌ＮａｎＨシアリダーゼＣＢＭ；
（ｖ）コレラ菌ＮａｎＨシアリダーゼＣＢＭのシアル酸結合断片；
（ｖｉ）肺炎レンサ球菌ｎａｎＡシアリダーゼＣＢＭ；および
（ｖｉｉ）肺炎レンサ球菌ｎａｎＡシアリダーゼＣＢＭのシアル酸結合断片、
からなる群から選択される、請求項５または６に記載の医薬組成物。 CBM is:
(i) Clostridium perfringens CBM32 (CpCBM32);
(ii) Streptococcus pneumoniae CBM40 (SpCBM40);
(iii) Vibrio cholerae CBM40 (VcCBM40);
(iv) Vibrio cholerae NanH sialidase CBM;
(v) sialic acid-binding fragment of Vibrio cholerae NanH sialidase CBM;
(vi) Streptococcus pneumoniae nanA sialidase CBM; and (vii) a sialic acid-binding fragment of Streptococcus pneumoniae nanA sialidase CBM;
The pharmaceutical composition according to claim 5 or 6, selected from the group consisting of.
（ｉ）ＨＶ６９－７０欠失；および／または
（ｉｉ）Ｎ５０１Ｙ；および／または
（ｉｉｉ）Ｅ４８４Ｋ、
のうちの１つ以上を含む、請求項９または１０に記載の医薬組成物。 Variants include the following spike protein mutations:
(i) HV69-70 deletion; and/or (ii) N501Y; and/or (iii) E484K,
11. A pharmaceutical composition according to claim 9 or 10, comprising one or more of:
（ｉ）コロナウイルス感染、コロナウイルスが引き起こすまたは原因となる疾患もしくは状態、および／またはコロナウイルス感染／疾患の症状；または
（ｉｉ）ＣＯＶＩＤ－１９、ＳＡＲＳ－ＣｏＶ－２が引き起こすまたは原因となる疾患もしくは状態、および／またはＣＯＶＩＤ－１９の症状
の処置または予防において使用するための医薬組成物。 Including CBM32,
(i) a coronavirus infection, a disease or condition caused or caused by a coronavirus, and/or symptoms of a coronavirus infection/disease; or (ii) a disease caused or caused by COVID-19, SARS-CoV-2. or condition, and/or a pharmaceutical composition for use in the treatment or prevention of symptoms of COVID-19.
AIIETAIPQSEMTASATSEEGQDPASSAIDGNTNTMWHTKWNGSDALPQSLSVNLGSSRKVSSIAITP
RTSGNNGFITKYEIHAINNGVETLVAEGTWEENNLVKTVTFDSPIDAEEIKITAIQGVGGFASIAELNVYE
またはそれのグリカン／炭水化物の結合断片
を含む、請求項１４に記載の医薬組成物。 CBM32 has the amino acid sequence of SEQ ID NO: 1:
AIIETAIPQSEMTASATSEEGQDPASSAIDGNTNTMWHTKWNGSDALPQSLSVNLGSSRKVSSIAITP
RTSGNNGFITKYEIHAINNGVETLVAEGTWEENNLVKTVTFDSPIDAEEIKITAIQGVGGFASIAELNVYE
or a glycan/carbohydrate binding fragment thereof .
（ｉ）コロナウイルス感染、コロナウイルスが引き起こすまたは原因となる疾患もしくは状態；または
（ｉｉ）ＣＯＶＩＤ－１９、ＳＡＲＳ－ＣｏＶ－２が引き起こすまたは原因となる疾患もしくは状態、および／またはＣＯＶＩＤ－１９の症状
の処置または予防において使用するための医薬組成物。 Including CBM40,
(i) a coronavirus infection, a disease or condition caused or caused by a coronavirus; or (ii) a disease or condition caused or caused by COVID-19, SARS-CoV-2, and/or symptoms of COVID-19. A pharmaceutical composition for use in the treatment or prevention of.
ALFDYNATGDTEFDSPAKQGWMQDNTNNGSGVLTNADGMPAWLVQGIGGRAQWTYSLSTNQHAQASSFGWRMTTEMKVLSGGMITNYYANGTQRVLPIISLDSSGNLVVEFEGQTGRTVLATGTAATEYHKFELVFLPGSNPSASFYFDGKLIRDNIQPTASKQNMIVWGNGSSNTDGVAAYRDIKFEIQGD
または配列番号６のアミノ酸配列：
VIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAFYNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRVRLYVNGVLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRS
またはいずれかのグリカン／シアル酸の結合断片
を含む、請求項１６に記載の医薬組成物。 CBM40 has the amino acid sequence of SEQ ID NO: 4:
ALFDYNATGDTEFDSPAKQGWMQDNTNNGSGVLTNADGMPAWLVQGIGGRAQWTYSLSTNQHAQASSFGWRMTTEMKVLSGGMITNYYANGTQRVLPIISLDSGNLVVEFEGQTGRTVLATGTAATEYHKFELVFLPGSNPSASFYFDGKLIRDNIQPTASKQNMIVWGNGSSNTDGVAAYRDIKFEIQGD
or the amino acid sequence of SEQ ID NO: 6:
VIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAFYNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRVRLYVNGVLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRS
or any glycan/sialic acid binding fragment .
（ｉ）コロナウイルス感染、コロナウイルスが引き起こすまたは原因となる疾患もしくは状態、および／またはコロナウイルス感染／疾患の症状；または
（ｉｉ）ＣＯＶＩＤ－１９、ＳＡＲＳ－ＣｏＶ－２が引き起こすまたは原因となる疾患もしくは状態、および／またはＣＯＶＩＤ－１９の症状
の処置または予防において使用するための医薬組成物。 including modified CBM;
(i) a coronavirus infection, a disease or condition caused or caused by a coronavirus, and/or symptoms of a coronavirus infection/disease; or (ii) a disease caused or caused by COVID-19, SARS-CoV-2. or condition, and/or a pharmaceutical composition for use in the treatment or prevention of symptoms of COVID-19.
GAMVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDPKAPAFYNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRSGGGSGVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDPKAPAFYNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRSGGSLGVPDFESDWFDVSSNSLYTLSHGLQRSPRRVVVEFARSSSPSTWNIVMPSYFNDGGHKGSGAQVEVGSLNIKLGTGAAVWGTGYFGGIDNSATTRFATGYYRVRAWI
またはそれのグリカン結合断片
を含む、請求項１８または１９に記載の医薬組成物。 The modified CBM has the sequence of SEQ ID NO : 17 :
GAMVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDPKAPAFYNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRSGGGSGVIEKEDVETNASNGQRVDLSSELD KLKKLENATVHMEFKPDPKAPAFYNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRSGGSLGVPDFESDWFDVSSNSLYTLSHGLQRSPRRVVVEFARSSSPSTWNIVMPSYFND GGHKGSGAQVEVGSLNIKLGTGAAVWGTGYFGGIDNSATTRFATGYYRVRAWI
or a glycan-binding fragment thereof.
（ｉ）コロナウイルス感染、コロナウイルスが引き起こすまたは原因となる疾患もしくは状態、および／またはコロナウイルス感染／疾患の症状；または
（ｉｉ）ＣＯＶＩＤ－１９、ＳＡＲＳ－ＣｏＶ－２が引き起こすまたは原因となる疾患もしくは状態、および／またはＣＯＶＩＤ－１９の症状；
の処置または予防において使用するための医薬組成物であって、
グリカン結合分子は：
（ｉ）Ｃｐ２ＣＢＭ３２ＴＤ（三量化ドメインに融合された、ウエルシュ菌由来の２つのＣＢＭ（ＣＢＭ３２）を含む、それから本質的になる、またはそれからなる）；
（ｉｉ）Ｓｐ２ＣＢＭ４０ＴＤ（三量化ドメインに融合された、肺炎レンサ球菌由来の２つのＣＢＭ（ＣＢＭ４０）を含む、それから本質的になる、またはそれからなる）；
（ｉｉｉ）Ｖｃ２ＣＢＭ４０ＴＤ（三量化ドメインに融合された、コレラ菌由来の２つのＣＢＭ（ＣＢＭ４０）を含む、それから本質的になる、またはそれからなる）；ならびに
（ｉｖ）Ｖｃ４ＣＢＭ（コレラ菌由来の４つのＣＢＭ（ＣＢＭ４０）を含む、それから本質的になる、またはそれからなる）、
からなる群から選択される、医薬組成物。 Contains glycan- binding molecules:
(i) a coronavirus infection, a disease or condition caused or caused by a coronavirus, and/or symptoms of a coronavirus infection/disease; or (ii) a disease caused or caused by COVID-19, SARS-CoV-2. or condition and/or symptoms of COVID-19;
A pharmaceutical composition for use in the treatment or prevention of
Glycan binding molecules are :
(i) Cp2CBM32TD (comprising, consisting essentially of, or consisting of two CBMs from Clostridium perfringens (CBM32) fused to a trimerization domain);
(ii) Sp2CBM40TD (comprising, consisting essentially of, or consisting of two CBMs from Streptococcus pneumoniae (CBM40) fused to a trimerization domain);
(iii) Vc2CBM40TD (comprising, consisting essentially of, or consisting of two CBMs from V. cholerae (CBM40) fused to a trimerization domain); and (iv) Vc4CBM (four CBMs from V. cholerae (CBM40), consisting essentially of, or consisting of (CBM40);
A pharmaceutical composition selected from the group consisting of .
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2003232.2A GB202003232D0 (en) | 2020-03-05 | 2020-03-05 | Treatment of viral infections |
| GB2003232.2 | 2020-03-05 | ||
| GB2004998.7 | 2020-04-04 | ||
| GBGB2004998.7A GB202004998D0 (en) | 2020-04-04 | 2020-04-04 | Treatment of viral infections |
| GBGB2006160.2A GB202006160D0 (en) | 2020-04-27 | 2020-04-27 | Treatment of viral infections |
| GB2006160.2 | 2020-04-27 | ||
| PCT/EP2021/055515 WO2021176017A1 (en) | 2020-03-05 | 2021-03-04 | Treatment of viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516995A JP2023516995A (en) | 2023-04-21 |
| JPWO2021176017A5 true JPWO2021176017A5 (en) | 2024-03-11 |
Family
ID=74867513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552577A Pending JP2023516995A (en) | 2020-03-05 | 2021-03-04 | Treatment of viral infections |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230125561A1 (en) |
| EP (1) | EP4114437A1 (en) |
| JP (1) | JP2023516995A (en) |
| KR (1) | KR20220150929A (en) |
| CN (1) | CN115297884A (en) |
| WO (1) | WO2021176017A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050137126A1 (en) * | 2003-04-09 | 2005-06-23 | Natlmmune A/S | Treatment of SARS in individuals |
| EP2533793B1 (en) * | 2010-02-12 | 2015-12-09 | Emory University | GAL-4 for use in the treatment of infectious diseases |
| WO2015110831A1 (en) * | 2014-01-24 | 2015-07-30 | University Court Of The University Of St Andrews | Immunomodulatory compounds |
| GB201800334D0 (en) * | 2018-01-09 | 2018-02-21 | Pneumagen Ltd | Modified protein |
-
2021
- 2021-03-04 US US17/905,303 patent/US20230125561A1/en active Pending
- 2021-03-04 EP EP21710907.3A patent/EP4114437A1/en active Pending
- 2021-03-04 CN CN202180018838.1A patent/CN115297884A/en active Pending
- 2021-03-04 JP JP2022552577A patent/JP2023516995A/en active Pending
- 2021-03-04 KR KR1020227034315A patent/KR20220150929A/en active Search and Examination
- 2021-03-04 WO PCT/EP2021/055515 patent/WO2021176017A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| White et al. | Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor | |
| EP3737402B1 (en) | Modified protein | |
| KR20050085130A (en) | Broad spectrum anti-viral therapeutics and prophylaxis | |
| White et al. | Enhanced antiviral and opsonic activity of a human mannose-binding lectin and surfactant protein D chimera | |
| US20240115659A1 (en) | Viral treatment | |
| US10953078B2 (en) | Treatment and/or prevention of sepsis | |
| JP2007137901A (en) | Method of using lipoprotein-associated coagulation inhibitor for treating septicemia | |
| JP5841841B2 (en) | Carbohydrate binding molecule | |
| Nikolaidis et al. | Mutations flanking the carbohydrate binding site of surfactant protein D confer antiviral activity for pandemic influenza A viruses | |
| US5981720A (en) | Human salivary proteins and fragments thereof having alpha-glucosidase inhibitory activity | |
| JPWO2021176017A5 (en) | ||
| JP3506274B2 (en) | New peptides and immunostimulants | |
| GB2593742A (en) | Coronavirus | |
| US20230125561A1 (en) | Treatment of viral infection | |
| EP3890768A1 (en) | Cancer treatment | |
| US20230054093A1 (en) | Treatment | |
| Indraratna et al. | The exploitation of human glycans by Group A Streptococcus | |
| JP2023546384A (en) | Use of triple active substance having activity against all glucagon, GLP-1 and GIP receptors to treat sequelae of respiratory infectious diseases | |
| Hartshorn et al. | Development of chimeric collectins with enhanced activity against influenza A virus | |
| Hartshorn et al. | Salivary Agglutinin and Lung Scavenger Receptor Rich Glycoprotein 340 Have Broad Anti-Influenza Activities and Interactions with Surfactant Protein D That Vary Based on Donor Source and Sialylation | |
| Madsen et al. | Surfactant protein D and Glycoprotein 340 | |
| KEMPER et al. | The Immunology of |